Last reviewed · How we verify
Calmeran — Competitive Intelligence Brief
phase 2
azacyclonol
Histamine H1 receptor, Sodium channel alpha subunits; brain (Types I, II, III)
Other
Small molecule
Live · refreshed every 30 min
Target snapshot
Calmeran (AZACYCLONOL). Calmeran works by blocking the histamine H1 receptor, which helps to reduce allergic responses and other physiological effects caused by histamine.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Calmeran TARGET | AZACYCLONOL | phase 2 | azacyclonol | Histamine H1 receptor, Sodium channel alpha subunits; brain (Types I, II, III) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (azacyclonol class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Calmeran CI watch — RSS
- Calmeran CI watch — Atom
- Calmeran CI watch — JSON
- Calmeran alone — RSS
- Whole azacyclonol class — RSS
Cite this brief
Drug Landscape (2026). Calmeran — Competitive Intelligence Brief. https://druglandscape.com/ci/azacyclonol. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing